%0 Journal Article
%9 ACL : Articles dans des revues avec comité de lecture non répertoriées par l'AERES
%A Rogier, C.
%A Brau, R.
%A Tall, A.
%A Cisse, B.
%A Trape, Jean-François
%T Reducing the oral quinine-quinidine-cinchonin (Quinimax) treatment of uncomplicated malaria to three days does not increase the recurrence of attacks among children living in a highly endemic area of Senegal
%D 1996
%L fdi:010005230
%G ENG
%J Transactions of the Royal Society of Tropical Medicine and Hygiene
%@ 0035-9203
%K PALUDISME ; CHIMIOPROPHYLAXIE ; TRAITEMENT MEDICAL ; SENSIBILITE RESISTANCE ; EFFICACITE ; ENFANT
%K QUININE ; QUINIDINE ; CINCHONINE ; QUINIMAX
%K SENEGAL
%N 2
%P 175-178
%R 10.1016/S0035-9203(96)90128-5
%U https://www.documentation.ird.fr/hor/fdi:010005230
%> https://horizon.documentation.ird.fr/exl-doc/pleins_textes/pleins_textes_6/b_fdi_43-44/010005230.pdf
%V 90
%W Horizon (IRD)
%X A 3 d shortened course of the quinine-quinidine-cinchonin association Quinimax (trademark) was compared to the usual 7 d regimen for routinely treating 462 acute uncomplicated #Plasmodium falciparum$ malaria attacks in 72 children under the age of 10 years in Dielmo, a holoendemic village in Senegal. 25 mg/kg Quinimax (trademark) salt daily, given in 3 equal doses, improved clinical status in 99.6% of the patients receiving the course and in all of those treated for 7 d. Even if the 3 d course did not systematically eliminate parasitaemia, reducing oral Quinimax (trademark) treatment of uncomplicated malaria from 7 to 3 d did not increase the recurrence of attacks, even among the youngest children. Both the quinine sensitivity of the Senegalese strains of #P. falciparum$ and the partial acquired immunity of the children were probably responsible for the absence of any difference between the courses. Oral Quinimax (trademark) for 3 d is a possible alternative regimen to chloroquine and sulfadoxine-pyrimethamine for treating uncomplicated malaria in highly endemic areas of Africa where clinical resistance to these drugs exists. (Résumé d'auteur)
%$ 052ANOPAL04